Search
for
Sort by
Research 31–60 of 135
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- ANÁLISE MICROBIOLÓGICA DE MATÉRIAS-PRIMAS E FORMULAÇÕES DE UMA FARMÁCIA DE MANIPULAÇÃO NA CIDADE DE VENÂNCIO AIRES/RS
- Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors
- Pharma in the bedroom . . . and the kitchen. . . . The pharmaceuticalisation of daily life
- Adverse effects of common medications on male fertility
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
- Repurposing existing drugs for COVID-19: an endocrinology perspective
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- New lifestyle drugs and somatoform disorders in dermatology
- The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
- Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
- Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study
- Common urologic diseases in older men and their treatment: how they impact fertility
- Post-finasteride syndrome – does it really exist?
- Non-surgical management of BPH: An updated review of current literature and state of the art on natural compounds and medical therapy
- Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
- Clinical Pearls in Men's Health
- Lifestyle Drugs in Old Age – A Mini-Review
- From Anti-Aging Medicine to Precision Healthspan Pharmacology: Evidence Domains, Monitoring Requirements, and Practical Boundaries
- Comparative Assessment of Topical Platelet-Rich Plasma and Phenytoin for Diabetic Foot Ulcer Healing in a Rat Model